To develop and conduct clinical trials aimed at improving the treatment and prevention of cancer with the ultimate goal of reducing morbidity and mortality from this disease.
The Canadian Cancer Trials Group is a cooperative oncology group which carries out clinical trials in cancer therapy, supportive care and prevention across Canada and internationally. It is one of the national programmes and networks of the Canadian Cancer Society Research Institute (CCSRI), and is supported by the Canadian Cancer Society (CCS).
InformationThe information contained in this website is intended for use by Canadian Cancer Trials Group members at participating centres.
Stereotactic Radiosurgery compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases
Marizomib with Standard Temozolomide-Based Radiochemotherapy vs Temozolomide-Based Radiochemotherapy Alone in Glioblastoma
Cisplatin + Rtx vs Durvalumab + Rtx followed by Durvalumab vs Durvalumab + Rtx followed by Tremelimumab and Durvalumab in HPV-Positive Oropharyngeal SCC
Tailor RT: Trial of Regional Rtx in Biomarker Low Risk Node Positive Breast Cancer
Hypofractionated Post-Mastectomy Rtx with Breast Reconstruction
Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women with BRCA 1/2 Mutations
InPACT: International Penile Advanced Cancer Trial
Durvalumab + Tremelimumab in Previously Treated Anti-PD-1/PD-L1 Resistant SCLC (Lung-MAP Non-Match Sub-Study)
Novel Therapeutics vs Azaciticine in Patients with AML or High Risk Myelodysplastic Syndrome, Aged 60 or Older (LEAP, Intergroup Less Intense AML Platform Trial)
Efficacy of the Addition of Inotuzumab Ozogamicin to Frontline Therapy in Young Adults with Precursor B-Cell ALL
Trimodality Therapy With/out Durvalumab to Treat Patients with Muscle-Invasive Bladder Cancer
BCG Strain Differences and T cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-naive High-grade Non-muscle Invasive Bladder Cancer
Nivolumab after Combined Modality Therapy in High-Risk Anal Cancer
Circulating Tumor DNA as a Predictive Marker for Response to Chemotherapy in Pts with Stage II Colon Ca
A Phase I Master Protocol of Novel Combination Therapy for Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma
Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]
Phase 3 RandOmized Study comparing PERioperative nivolumab vs observation in Renal Cell Carcinoma undergoing nephrectomy (PROSPER RCC)
MK-3475 for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes After Neoadjuvant Chemotherapy